Dabrafenib (GSK2118436) - CAS 1195765-45-7
Catalog number:
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Dabrafenib (GSK2118436) is a mutant BRAFV600 specific inhibitor with IC50 of 0.8 nM, with 4- and 6-fold less potency against B-Raf(wt) and c-Raf, respectively.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-454193 250 mg $298 In stock
Bulk Inquiry
Publictions citing BOC Sciences Products
  • >> More
Related CAS:
1195768-06-9 (mesylate salt)
1.Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial.
Planchard D1, Kim TM2, Mazieres J3, Quoix E4, Riely G5, Barlesi F6, Souquet PJ7, Smit EF8, Groen HJ9, Kelly RJ10, Cho BC11, Socinski MA12, Pandite L13, Nase C14, Ma B15, D'Amelio A Jr16, Mookerjee B17, Curtis CM Jr18, Johnson BE19. Lancet Oncol. 2016 Apr 11. pii: S1470-2045(16)00077-2. doi: 10.1016/S1470-2045(16)00077-2. [Epub ahead of print]
BACKGROUND: Activating BRAFV600E (Val600Glu) mutations are found in about 1-2% of lung adenocarcinomas, which might provide an opportunity for targeted treatment in these patients. Dabrafenib is an oral selective inhibitor of BRAF kinase. We did a trial to assess the clinical activity of dabrafenib in patients with advanced non-small-cell lung cancer (NSCLC) positive for the BRAFV600E mutation.
2.Simultaneous quantification of dabrafenib and trametinib in human plasma using high-performance liquid chromatography-tandem mass spectrometry.
Nijenhuis CM1, Haverkate H2, Rosing H2, Schellens JH3, Beijnen JH4. J Pharm Biomed Anal. 2016 Mar 25;125:270-279. doi: 10.1016/j.jpba.2016.03.049. [Epub ahead of print]
Dabrafenib (Tafinlar®) and trametinib (Mekinist®) are registered for the treatment of patients with BRAF V600 mutation positive unresectable or metastatic melanoma. To support therapeutic drug monitoring (TDM) and clinical pharmacological trials, an assay to simultaneously quantify dabrafenib and trametinib in human plasma using liquid chromatography tandem mass spectrometry was developed and validated. Human plasma samples were collected on an outpatient base and stored at nominally -20°C. Analytes and internal standards (stable isotope labeled compounds) were extracted with TBME. After snap freezing the samples in a dry ice-ethanol bath, the organic layer was transferred to a clean tube and evaporated under a gentle stream of nitrogen gas. The dry extract was then reconstituted with 100μL acetonitrile and 5μL of the final extract was injected and separated on a C18 column with gradient elution, and analyzed with triple quadrupole mass spectrometry in positive-ion mode.
3.Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial.
Chen G1, McQuade JL2, Panka DJ3, Hudgens CW4, Amin-Mansour A5, Mu XJ5, Bahl S5, Jané-Valbuena J5, Wani KM4, Reuben A6, Creasy CA1, Jiang H6, Cooper ZA6, Roszik J1, Bassett RL Jr7, Joon AY7, Simpson LM1, Mouton RD1, Glitza IC1, Patel SP1, Hwu WJ1, Amaria R JAMA Oncol. 2016 Apr 28. doi: 10.1001/jamaoncol.2016.0509. [Epub ahead of print]
Importance: Combined treatment with dabrafenib and trametinib (CombiDT) achieves clinical responses in only about 15% of patients with BRAF inhibitor (BRAFi)-refractory metastatic melanoma in contrast to the higher response rate observed in BRAFi-naïve patients. Identifying correlates of response and mechanisms of resistance in this population will facilitate clinical management and rational therapeutic development.
4.The relative clinical efficacy of trametinib-dabrafenib and cobimetinib-vemurafenib in advanced melanoma: an indirect comparison.
Galván-Banqueri M1, Ubago-Pérez R1, Molina-López T1. J Clin Pharm Ther. 2016 Apr 15. doi: 10.1111/jcpt.12390. [Epub ahead of print]
WHAT IS KNOWN AND OBJECTIVE: Melanoma causes the majority of skin cancer-related deaths. The outcome of melanoma depends on its stage at diagnosis. Currently, for patients with advanced melanoma, two MEK inhibitors (trametinib and cobimetinib) have been authorized by the European Medicines Agency. The main objective of this study was to compare the relative efficacy of trametinib-dabrafenib and cobimetinib-vemurafenib in patients with advanced melanoma through adjusted indirect treatment comparisons (ITCs).
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Raf Products

CAS 905281-76-7 GDC-0879

(CAS: 905281-76-7)

GDC-0879, a highly selective, potent, and orally bioavailable RAF small-molecule inhibitor. In GDC-0879-treated mice, both cell line- and patient-derived BRAF(...

CAS 1315329-43-1 HG6-64-1

(CAS: 1315329-43-1)

HG6-64-1 is a potent and selective B-Raf and mutant B-Raf inhibitor; more information can be found in Patent WO 2011090738.

CAS 927880-90-8 RAF265

(CAS: 927880-90-8)

RAF265 is a potent selective inhibitor of C-Raf/B-Raf/B-Raf V600E with IC50 of 3-60 nM, and exhibits potent inhibition on VEGFR2 phosphorylation with EC50 of 30...

CAS 1315330-11-0 B-Raf inhibitor

B-Raf inhibitor
(CAS: 1315330-11-0)

aA B-Raf inhibitor, pyrazine and pyrrolo[2,3-b]pyridine derivatives, useful in the treatment of cancer and proliferative diseases.

(CAS: 1163719-91-2)

This active molecular is a novel , paradox-breaking pan-RAF inhibitor with anti-SRC activity and it blocked growth of BRAF-mutant and NRAS-mutant melanoma cells...

(CAS: 870603-16-0)

BMS-908662 is a Raf kinase inhibitor with potential antineoplastic activity. It can specifically inhibit RAF kinases, located downstream from RAS in the RAS/RAF...

(CAS: 1269440-29-0)

Encorafenib is a Proto oncogene protein b raf inhibitor with potential antineoplastic activity. By inhibiting the activation of the RAF/MEK/ERK signaling pathwa...

CAS 284461-73-0 Sorafenib tosylate

Sorafenib tosylate
(CAS: 284461-73-0)

Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM, respectively.

CAS 1188910-76-0 CEP-32496

(CAS: 1188910-76-0)

CEP-32496 is a highly potent inhibitor of BRAF(V600E/WT) and c-Raf with Kd of 14 nM/36 nM and 39 nM, also potent to Abl-1, c-Kit, Ret, PDGFRβ and VEGFR2, respec...

(CAS: 1393465-84-3)

PLX7904, also known as PB04, is a potent and selective paradox-breaker RAF inhibitor. PB04 is able to efficiently inhibit activation of ERK1/2 in mutant BRAF me...

CAS 1093100-40-3 B-Raf inhibitor 1

B-Raf inhibitor 1
(CAS: 1093100-40-3)

B-Raf inhibitor 1 is a potent and selective B-Raf inhibitor with cell IC50s of 0.31 μM and 2 nM for A375 proliferation and A375 p-ERK respectively.

(CAS: 1446090-77-2)

BGB-283 is a selective Epidermal growth factor receptor and Proto oncogene protein b raf inhibitor under the development of BeiGene. BGB-283 shows antitumor act...

ARQ 736 disodium salt
(CAS: 1228237-57-7)

This active molecular is a Proto oncogene protein b raf and Vascular endothelial growth factor A inhibitor originated by ArQule. ARQ 736 is effective in killing...

(CAS: 40554-55-4)

SB-590885 is a selectively Raf kinases inhibitor, stabilizes the oncogenic B-Raf kinase domain in an active configuration, which is distinct from the previously...

CAS 950736-05-7 B-Raf IN 1

B-Raf IN 1
(CAS: 950736-05-7)

B-Raf IN 1 is a highlt potent and selective B-Raf inhibitor. It was equipotent against c-Raf.

CAS 208260-29-1 ZM336372

(CAS: 208260-29-1)

ZM336372 is a Raf-1 activating agent, has been shown to cause growth inhibition and suppression of hormone secretion in a neuroendocrine cell line. ZM336372 cau...

CAS 918504-65-1 Vemurafenib

(CAS: 918504-65-1)

Vemurafenib is a potent and selective inhibitor of B-RafV600E with IC50 of 13 nM, equally potent to c-Raf-1(Y340D and Y341D mutations), 10-fold selectivity than...

CAS 405554-55-4 SB-590885

(CAS: 405554-55-4)

SB-590885 is a novel triarylimidazole that selectively inhibits Raf kinases. SB-590885 stabilizes the oncogenic B-Raf kinase domain in an active configuration....

CAS 878739-06-1 AZ 628

AZ 628
(CAS: 878739-06-1)

AZ628 is a potent, ATP-competitive inhibitor of Raf kinases (IC50 values are 29, 34 and 105 nM for c-Raf1, B-RafV600E and wild-type B-Raf, respectively). It dis...

(CAS: 1454682-72-4)

LY03009120 is a potent pan-Raf inhibitor with IC50 of 44 nM, 31-47 nM, and 42 nM for A-raf, B-Raf, and C-Raf in A375 cells, respectively. Phase 1.

Chemical Structure

CAS 1195765-45-7 Dabrafenib (GSK2118436)

Quick Inquiry

Verification code

Featured Items